TEVIMBRA Beigene Aus Pty Ltd
Product name
TEVIMBRA
Sponsor
Accepted date
Apr-2024
Active ingredients
tislelizumab
Proposed indication
Indicated for the first-line treatment of locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma.
Application type
A (new medicine)
Publication date
Apr-2024